The hemoglobin switch -- repression of ?-globin and activation of ?-globin expression during the transition from fetal to adult stages of erythropoiesis -- is a major paradigm for cell and developmental stage specific regulation. Given family and genetic studies demonstrating the beneficial effects of increased HbF (?2?2) in the ?-hemoglobin disorders -- sickle cell disease (SCD) and ?-thalassemia -- efforts have been directed towards manipulating the switch as a therapeutic approach. A major obstacle, however, has been ignorance regarding how the switch is achieved and ?-globin silencing is maintained in the adult. Work in our group over the past several years has established the repressor protein BCL11A as a central, quantitative regulator of the switch. Moreover, critical sequences in an erythroid-specific enhancer within the BCL11A gene are required for its expression, providing a target site for gene editing as an improved form of gene therapy for patients with ?-hemoglobin disorders. The remaining challenge now is development of therapeutic strategies based on modulation of BCL11A function with small molecules, as a means to bring mechanism-based therapy to wider populations. In this project we will focus on the BCL11A protein and address three aspects. First, following our identification of components of the nuclear matrix in association with BCL11A protein complexes, we will dissect the functional relationship between chromatin and the nuclear matrix in erythroid cells. Second, with the goal of reducing the level of BCL11A protein and relieving HbF repression, we will employ genetic and small molecule screens to test the possibility that inhibition of deubiquitylases might constitute a new therapeutic approach to HbF reactivation. Third, we will perform saturating CRISPR/Cas9 mutagenesis of the human A??? intergenic region to localize sequences required for full HbF repression, and correlate these with chromatin sites proposed to bind BCL11A. In this manner, we will identify critical cis-acting sequences bound by BCL11A, ascertain whether these are sites of chromatin-nuclear matrix interaction, and define additional DNA sequences for therapeutic genome editing. The goal of this project is to capitalize on our discovery of BCL11A as a major regulator of the hemoglobin switch and develop innovative, and non-traditional, therapeutic approaches to the hemoglobin disorders.

Public Health Relevance

Prior to birth, the principal hemoglobin in our red blood cells is fetal hemoglobin (HbF), whereas after birth, the major hemoglobin is an adult type, designated HbA. The genetic diseases, sickle cell disease (SCD) and ?-thalassemia (Cooley's anemia), are among the most prevalent genetic conditions and affect several million individuals worldwide. It is well established that HbF is able to replace HbA and ameliorate the severity of the hemoglobin disorders. Therefore, a major goal of our research is to develop methods to reactivate HbF in adults for therapy. This project is designed to develop new leads to achieve this challenging goal.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL032262-36
Application #
9474161
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Qasba, Pankaj
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
36
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Boston Children's Hospital
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
Yu, Shan-He; Zhu, Kang-Yong; Zhang, Fan et al. (2018) The histone demethylase Jmjd3 regulates zebrafish myeloid development by promoting spi1 expression. Biochim Biophys Acta Gene Regul Mech 1861:106-116
Parada-Kusz, Margarita; Penaranda, Cristina; Hagedorn, Elliott J et al. (2018) Generation of mouse-zebrafish hematopoietic tissue chimeric embryos for hematopoiesis and host-pathogen interaction studies. Dis Model Mech 11:
Rost, Megan S; Shestopalov, Ilya; Liu, Yang et al. (2018) Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish. Blood Adv 2:3418-3427
Lahvic, Jamie L; Ammerman, Michelle; Li, Pulin et al. (2018) Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. Proc Natl Acad Sci U S A 115:9252-9257
Liu, Nan; Hargreaves, Victoria V; Zhu, Qian et al. (2018) Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell 173:430-442.e17
Whitman, Jared C; Paw, Barry H; Chung, Jacky (2018) The role of ClpX in erythropoietic protoporphyria. Hematol Transfus Cell Ther 40:182-188
Mandelbaum, Joseph; Shestopalov, Ilya A; Henderson, Rachel E et al. (2018) Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma. J Exp Med 215:2673-2685
Kapp, Friedrich G; Perlin, Julie R; Hagedorn, Elliott J et al. (2018) Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche. Nature 558:445-448
Yamauchi, Takuji; Masuda, Takeshi; Canver, Matthew C et al. (2018) Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Cancer Cell 33:386-400.e5
Gehrke, Jason M; Cervantes, Oliver; Clement, M Kendell et al. (2018) An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. Nat Biotechnol 36:977-982

Showing the most recent 10 out of 215 publications